In Vitro Development of Resistance to Ofloxacin and Doxycycline in Bacillus anthracis Sterne

Abstract

Anthrax is an infection caused by Bacillus anthracis. It occurs endemically and could also be used for biological warfare with devastating effects (3). The worldwide increase in the development of drug resistance in bacteria is a major concern. This phenomenon can develop after in vitro challenges (1) and/or following extensive clinical use of antibiotics (2). This prompted us to determine if B. anthracis could also develop resistance to the currently recommended antibiotics for the treatment of anthrax infection.B. anthracis Sterne spores were harvested from batch fermentation in Schaeffer's sporulation medium using live veterinary vaccine as seed (Colorado Serum Co., Denver, Colo.). Spores were stored at Ϫ70°C in 10% glycerol-water. The spores were thawed and incubated in brain heart infusion broth (Becton Dickinson & Co., Rutherford, N.J.) at 37°C for 24 h. The antimicrobials used were ofloxacin (Ortho Pharmaceutical Corp., Raritan, N.J.) and doxycycline (Abbott Laboratories, Chicago, Ill.).MICs were determined by macrodilution methodology in brain heart infusion broth inoculated with 10 7 CFU from an overnight culture per ml and incubated for 24 h at 37°C. Glass tubes containing 4.5 ml of brain heart infusion with doubling (ratio of 1:2) antibiotic dilutions were each inoculated with 0.1 ml of suspension containing approximately 10 5 CFU of B. anthracis Sterne per ml. The range of inoculated dilutions was from 2 below to 11 above the MIC. A total of 18 passages were performed where the inoculum for each successive passage was taken from the first tube below the MIC. The cells were subcultured before each passage and at the end of the 18 passages on sheep blood agar medium without antibiotics and visually verified.Repeated subculturing of B. anthracis led to an increase in the MIC of ofloxacin on the 13th passage from an initial MIC of 0.2 to 0.8 g/ml. The MIC of 0.8 g/ml was stable for the next five passages. The MIC of doxycycline did not change after 18 passages. The MIC of ofloxacin for B. anthracis from passage 1 was 0.2 g/ml, and the MIC of ofloxacin for B. anthracis of passage 13 was 0.8 g/ml. This was repeated five times with the same results.This pilot study shows the development in vitro of increased levels of resistance of B. anthracis to a quinolone. Although the increase in the MIC of ofloxacin was only fourfold, from 0.2 to 0.8 g/ml, which still makes the organism susceptible to ofloxacin, it signifies the potential for emergence of resistance. The development of decreased susceptibility to ofloxacin raises a serious concern for public safety since quinolones are currently the recommended therapy for anthrax (3). It was reassuring, however, to find that resistance to doxycycline did not develop.The study has several limitations. It included only one strain of B. anthracis, Sterne (the strain used for animal vaccination), and only a limited number of passages were done. Further studies are therefore necessary with a lethal strain of B. anthracis.The mechanism by which B. anthracis develops resist...

Antimicrobial Susceptibility Testing of Bacillus anthracis : Comparison of Results Obtained by Using the National Committee for Clinical Laboratory Standards Broth Microdilution Reference and Etest Agar Gradient Diffusion Methods

“…Doxycycline, which was listed in the CDC recommendations as the other primary therapeutic agent for the treatment and prophylaxis of inhalational anthrax (3), was also highly active against the B. anthracis strains in our study (MICs, Յ0.015 g/ml). The attempts of Choe et al (5) to increase the doxycycline MIC were unsuccessful.…”

MICs of Selected Antibiotics forBacillus anthracis,Bacillus cereus,Bacillus thuringiensis, andBacillus mycoidesfrom a Range of Clinical and Environmental Sources as Determined by the Etest

“…The development of reduced susceptibility of B. anthracis to the quinolone ofloxacin but not to doxycycline following sequential subculture in subinhibitory concentrations has been demonstrated (8). The relatively low proportion of B. anthracis strains fully susceptible to erythromycin (15%) was somewhat surprising in view of the fact that this drug was regarded from the earliest days of antimicrobial chemotherapy (14) as an effective alternative to penicillin and is usually listed as such in medical microbiology texts.…”

Daptomycin exerts rapid bactericidal activity against Bacillus anthracis without disrupting membrane integrity

“…For example, although penicillin is considered the treatment of choice for all forms of anthrax, many penicillin-resistant strains and treatment failures have been reported in the literature [5][6][7] . Reports of B anthracis resistance to ciprofloxacin and other antibiotics have likewise appeared [8][9][10][11] . It is, therefore, important to reevaluate the spectrum of antibiotics and to develop new drugs that are available for anthrax treatment.…”